Condition: Advanced/Metastatic Solid Tumors · Sponsor: Shanghai Henlius Biotech
This study is an open-label first-in-human phase I clinical study to evaluate the safety, tolerability, and pharmacokinetic characteristics of HLX48 in patients with advanced/metastatic solid tumors.
This description comes directly from the study's public registry record.
Ruihua Xu · 86-20-87343468 · Emailxurh@sysucc.org.cn
Always discuss trial participation with your own doctor first.
| Macquarie University | North Ryde, New South Wales, Australia | Not Yet Recruiting |
| GenesisCare St.Leonards | Saint Leonards, New South Wales, Australia | Not Yet Recruiting |
| Peninsula and South Eastern Haematology and Oncology Group | Frankston, Victoria, Australia | Not Yet Recruiting |
| Zhujiang Hospital of Southern Medical University | Guangzhou, Guangdong, China | Not Yet Recruiting |
| Sun Yat-Sen University Cancer Center | Guangzhou, Guangzhou, China | Recruiting |
| Shanghai General Hospital | Hongkou, Shanghai Municipality, China | Recruiting |
| Shanxi Provincial Cancer Hospital | Taiyuan, Shanxi, China | Not Yet Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07473726